Previous Close | 2.02 |
1-Year Change | -15.13% |
6-Months Change | -48.21% |
3-Months Change | -44.35% |
Moving Avg (50d) | 3.1134 |
Moving Avg (200d) | 4.4806 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 199.1M |
Beta (3-Years) | 1.97 |
Revenue Growth (ttm) | 53.9% |
Net Profit Margin (ttm) | -163.04% |
Return On Assets (ttm) | -31.84% |
EPS (ttm) | -1.77 |
PE Ratio (ttm) | -1.14 |
Dividend Yield | % |
Asset Description: | Fate Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-11-07 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.336 | 2.404 | 2.45 | 2.519 | 2.633 | 2.748 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |